ReviewThe Journal of clinical investigation2008
The anticancer immune response: indispensable for therapeutic success?
Review in The Journal of clinical investigation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 294 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
294 citing papers in PubMed, 3 syntheses or guidelines pooled it, 557 citations in OpenAlex.
- Switch Maintenance Therapy for Metastatic Urothelial Carcinoma.Bladder cancer (Amsterdam, Netherlands) · 2022Pooled it
- Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.Advanced drug delivery reviews · 2020Pooled it
- Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors.Journal of the National Comprehensive Cancer Network : JNCCN · 2015Pooled it
- The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer.Breast cancer research : BCR · 2026Trial
- Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.Journal of immunology (Baltimore, Md. : 1950) · 2023Trial
- Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.Molecular oncology · 2022Trial
- Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial.AIDS research and therapy · 2022Trial
- Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases.The journal of pathology. Clinical research · 2022Trial
- A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.Annals of surgery · 2013Trial
- HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.Journal of translational medicine · 2013Trial
- Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2013Trial
- Nanoadjuvant-integrated organic biomaterials for immune engineering: Mechanisms, design strategies, and translational applications.Materials today. Bio · 2026Review
- Athymic murine models can underestimate the immune-dependent components of chemotherapy efficacy.Frontiers in immunology · 2026Review
- Treatment outcomes of dogs with transitional cell carcinoma.Frontiers in veterinary science · 2025Article
- Emerging Research and Future Directions on Doxorubicin: A Snapshot.Asian Pacific journal of cancer prevention : APJCP · 2025Review
- Predictors of postoperative recurrence in locally advanced gastric cancer patients achieving pathological complete response after neoadjuvant therapy: a matched case-control study.Frontiers in oncology · 2025Article
- Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report.Frontiers in oncology · 2025Article
- Article
- Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective.Vaccines · 2024Review
- Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
234 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the impact of tumor immunology on the clinical management of most cancers is still negligible, there is increasing evidence that anticancer immune responses may contribute to the control of cancer after conventional chemotherapy. Thus, radiotherapy and some chemotherapeutic agents, in particular anthracyclines, can induce specific immune responses that result either in immunogenic cancer cell death or in immunostimulatory side effects. This anticancer immune response then helps to eliminate residual cancer cells (those that fail to be killed by chemotherapy) or maintains micrometastases in a stage of dormancy. Based on these premises, in this Review we address the question, How may it be possible to ameliorate conventional therapies by stimulating the anticancer immune response? Moreover, we discuss the rationale of clinical trials to evaluate and eventually increase the contribution of antitumor immune responses to the therapeutic management of neoplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.